TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of oral glucose tolerance test (OGTT) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in The Thriving of Older People Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in relatives' satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in staff's job satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ECG recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Laboratory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulated incidence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time for lung recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change From Baseline in 7-Point Glucose Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinician-administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Days of Heavy Drinking
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient-reported PTSD Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Partner-reported PTSD Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score in the virtual vitreoretinal training program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycemic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frailty assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticospinal Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leisure-Time Exercise Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-Week Step Count Measurement with Pedometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome 1 year after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Regression in language and behaviour skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of folliculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Reclassification Index (NRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nighttime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difficulties with Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-randomization rate of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Serum Concentration (Ctrough) of Pertuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neural activity measured by BOLD fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with adverse events (AEs) including serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time to CMV viral load negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in University of Washington - Quality of Life (UW-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Hospital Anxiety & Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Exercise and Muscle Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Taking Ivabradine at 180 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of MRD-negativity in the bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient Activation Measure (PAM) Level Greater Than 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scar evaluation scale for short term esthetic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rotational stability of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total LA consumption at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety in terms of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: child's quality and social capacity for joint attention/social interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: parents' sensitivity/responsitivity to children's behaviour/signals
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Best Corrected Visual Acuity (BCVA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Problem Checklist (BPC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Top Problems Assessment (TPA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropsychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of hospital admissions for febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of endothelium-dependent vasodilation (%FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heat Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat Pain Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophizing score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulty in Emotions Regulation score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: all-cause mortality during hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac mortality during hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Changes in microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative major morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Cell Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Objective Tumor Regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Treatment Related Adverse Events Related to T-Cell Receptor (TCR) Gene-Engineered Cells
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with vital sign abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with laboratory value abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of HBV DNA reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Lymphoproliferative Disorders (LPD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Lymphoma
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Important Infections
Endpoint domain: Adverse events/effects
Primary endpoint: 6 minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Urotensin II (UII) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Lumbar Puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of cardiorespiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DMFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical Index (PAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of pulpal and periapical diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of post operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peds QL questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immunosuppressant Therapy Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients transfused at least one unit of packed red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: steady state Cmax, Cmin, AUC0-12h, and t1/2 of RTV and IDV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary stability countertorque measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Bleeding Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrial function of postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of total radiolabelled 14C-content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of parent AAI101
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Body weight and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety Measured by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Pain Intensity Difference at 30 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility between experts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment for Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean Post-treatment Microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hours Spent in Pediatric ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of FOGQ score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Arrhythmogenic burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of cysticercosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of neurocysticercosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical effect evaluated on clinical score scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Toe taps on force plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG data of both lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with HbA1c ≤ 6.5% at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects free of severe hypoglycemic events from Day 28 to Day 365
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Compassion Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calprotectin level in ascitic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic endocrine function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: R-wave Amplitudes Greater Than or Equal to 200 μV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gag score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal dopamine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychoactive effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Navicular drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diameter of tibialis posterior vein in supine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flow velocity of tibialis posterior vein in supine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Volume flow of tibialis posterior vein in supine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diameter of tibialis posterior vein during weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flow velocity of tibialis posterior vein during weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in thalamus pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean cocaine inter-infusion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women over-estimating IVF-live birth rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Rise of Direct Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Patients With Adequate Biliary Drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Best overall immune response rate (iBOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in body mass indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of ventricular function recovery (left ventricular ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination coverage at birth
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS (Visual Analog Scale) at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of Plasma expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone loss as measured by CT of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharmacokinetic parameters (Cmax, Tmax, AUC0-t, AUC0-∞, t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Health Index (VHI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypersensitivity pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obtained Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Average Number of Days Worked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Average Number of Hours Worked Per Week For Those Who Worked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: survival rate of dental implants
Endpoint domain: Mortality/survival
Primary endpoint: stability of dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bony changes around dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of stability test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: m-CTSIB test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall risk test (FR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biotin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of bicalutamide in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of bicalutamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Satisfaction as Assessed by 4-point Likert Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Added Sugar Intake (Teaspoons/Day) Among Total Sample at Follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of alcoholic drinks consumed per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of patients free from device-related major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: SARS CoV 2 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of SHR4640 and Febuxostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of SHR4640 and Febuxostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seroprotection to Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Booster Response to Vaccine Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Antibodies to ADACEL Polio Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of Antibodies to Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: New or Worsening Transplant Glomerulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall aesthetic improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing ≥1 Adverse Event(s) (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in subjective Tinnitus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of the Terminal Elimination Half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Successfully Completed SPECT/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter tip fungal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of deep incisional surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Inhaler Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes